Haleon is beefing up its stake in Chinese OTC joint venture TSKF and has secured an option to take full control of the business in the future.
Haleon Strengthens Control Of China JV, Agrees Option To Buy
Joint venture business which markets Haleon's OTC drug brands in China will soon be 88% owned by the UK-based firm.
More from China
• By
Haleon now holds 88% of its China OTC joint venture after acquiring a larger stake in the business from its local partners.
• By
APAC health agencies such as WHO and Thailand's FDA are on board with the self-care agenda, and see it as crucial to achieving universal health coverage.
• By
Haleon highlighted consistent market share gains in China as it reported third-quarter results.
• By
Joint venture business which markets Haleon's OTC drug brands in China will soon be 88% owned by the UK-based firm.
More from Asia
• By
GSCF research shows that self-care already saves the Asia Pacific region more than $30bn a year in healthcare system costs. To realize higher gains, health literacy, Rx-to-OTC switch and digitalization need to be leveraged, according to the EU-ASEAN Business Council.
• By
APAC health agencies such as WHO and Thailand's FDA are on board with the self-care agenda, and see it as crucial to achieving universal health coverage.
• By
A round-up of recent consumer health appointments: PharmaSGP names new CEO; Stada appoints Vietnam head; NèreS adds to board.